<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04720339</url>
  </required_header>
  <id_info>
    <org_study_id>7652</org_study_id>
    <nct_id>NCT04720339</nct_id>
  </id_info>
  <brief_title>Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.</brief_title>
  <official_title>Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-small cell lung cancer (NSCLC) is a major public health problem. New treatments as&#xD;
      immunotherapy can improve prognosis of patients with NCLC tumors. Nevertheless, no robust&#xD;
      biomarker is actually available.&#xD;
&#xD;
      The hypothesis of the trial is to realize a longitudinal molecular monitoring of NSCLC&#xD;
      patients treated by immunotherapy using a quantitative analysis of cell-free DNA.&#xD;
&#xD;
      The primary purposes is to study the predictive value of quantification of cell-free DNA at&#xD;
      the first reevaluation time, on the clinical benefit, in NSCLC patients treated by&#xD;
      immunotherapy (regardless of line, or associated treatments) The secondary purposes in this&#xD;
      population of patients is to study the earlier predictive value (before the second treatment&#xD;
      by immunotherapy ) of quantification of cell-free DNA, and its relationship with refractory&#xD;
      disease and pseudo-progressive disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2021</start_date>
  <completion_date type="Anticipated">October 27, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 27, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive value of quantification of cell-free DNA from plasma at the time of the first radiological evaluation, on clinical benefit</measure>
    <time_frame>Inclusion visit - visit 2 (day 60)</time_frame>
    <description>The quantification of cell-free DNA is realized by droplet digital PCR (ddPCR) using two house-keeping genes (RPP30, ASL); if a somatic mutation is identified in the paired tumor DNA in routine practice, this mutation is also quantify in the cell-free DNA from plasma. The quantification of cell-free DNA corresponds to the variation from the time at inclusion and the time at the first radiological evaluation.&#xD;
The clinical benefit is defined by the duration of treatment by immunotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study of the earlier predictive value (before the second treatment by immunotherapy ) of quantification of cell-free DNA, and its relationship with refractory disease and pseudo-progressive disease.</measure>
    <time_frame>Inclusion visit, visit 1 (day 15), visit 2 (day 60), visit 3 (day 180), visit 4 (day 270), visit 5 (day 360), visit 6 (day 720), or early termination visit (in case of progression with end of immunotherapy)</time_frame>
    <description>The quantification of cell-free DNA is realized by droplet digital PCR (ddPCR) using two house-keeping genes (RPP30, ASL); if a somatic mutation is identified in the paired tumor DNA in routine practice, this mutation is also quantify in the cell-free DNA from plasma.&#xD;
The earlier quantification of cell-free DNA corresponds to the variation from the time at inclusion and the time before the second administration of immunotherapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>NSCLC</condition>
  <condition>IMMUNOTHERAPY</condition>
  <condition>QUANTIFICATION OF CELL-FREE DNA</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Molecular monitoring by quantification of cell-free DNA</intervention_name>
    <description>Molecular monitoring by quantification of cell-free DNA (absolute value and variation from baseline) of two house-keeping genes (RPP30, ASL) by droplet digital PCR, during based-immunotherapy treatments of NSCLC patients.&#xD;
Cell-free DNA will be extracted from 4 ml of plasma before treatments by immunotherapy, obtained from blood Streck® tubes.&#xD;
Quantification of house-keeping genes (or mutated genes if some are previously routinely identified in tumor tissue) by ddPCR.</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age over 18&#xD;
&#xD;
          -  informed of the objectives of the project and signed consent&#xD;
&#xD;
          -  non small cell lung cancer, stage IIIB to IV&#xD;
&#xD;
          -  PS &lt;1&#xD;
&#xD;
          -  treatment based on immunotherapy (monotherapy or combination)&#xD;
&#xD;
          -  at least one measurable target&#xD;
&#xD;
          -  available results of PD-L1 expression&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  concomitant other type of cancer&#xD;
&#xD;
          -  another cancer in the last 5 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BEAU-FALLER Michelle, MD</last_name>
    <phone>+33 3 88 12 84 57</phone>
    <email>Michele.FALLER@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Besancon - Service de pneumologie</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>WESTEEL Virginie, MD</last_name>
      <phone>+33 3 81 66 81 66</phone>
      <email>virginie.westeel@univ-fcomte.fr</email>
    </contact>
    <investigator>
      <last_name>WESTEEL Virginie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux Civils de Colmar - service de Pneumologie</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MOREAU Lionel, MD</last_name>
      <phone>+33 3 89 12 40 00</phone>
      <email>lionel.moreau@ch-colmar.fr</email>
    </contact>
    <investigator>
      <last_name>MOREAU Lionel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon - service de Pneumologie</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FOUCHER Pascal, MD</last_name>
      <phone>+33 3 80 29 30 31</phone>
      <email>pascal.foucher@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>FOUCHER Pascal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CLCC Georges-François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>KADERBHAI Courèche, MD</last_name>
      <phone>+33 3 80 73 75 28</phone>
      <email>CGKaderbhai@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>KADERBHAI Courèche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GHR Mulhouse Sud-Alsace - Service de Pneumologie</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DEBIEUVRE Didier, MD</last_name>
      <phone>+33 03 89 64 73 96</phone>
      <email>debieuvred@ch-mulhouse.fr</email>
    </contact>
    <investigator>
      <last_name>DEBIEUVRE Didier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Reims - service de Pneumologie</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DEWOLF Maxime, MD</last_name>
      <phone>+33 3 26 78 78 78</phone>
      <email>mdewolf@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>DEWOLF Maxime, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>DESLEE Gaëtan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BEAU-FALLER Michele, MD</last_name>
      <phone>+33 388128457</phone>
      <email>Michele.FALLER@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>MASCAUX Céline, MD</last_name>
      <phone>+33 369550195</phone>
      <email>Celine.MASCAUX@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>BEAU-FALLER Michele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>PAMART Guillaume, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MATAU César, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>PABST Lucile, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MENNECIER Bertrand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>CLEMENT-DUCHENE Christelle, MD</last_name>
      <phone>+33 3 83 59 83 31</phone>
      <email>c.clementduchene@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>CLEMENT-DUCHENE Christelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Cell-free DNA</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Digital PCR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

